Semler Scientific, Inc. (SMLR)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Semler Scientific, Inc. (“Semler” or “the Company”) (NASDAQ: SMLR). Investors who purchased Semler securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Semler has violated federal securities laws.

Investigation Details

On February 28, 2025, Semler filed its annual report for full year 2024 and disclosed that “there is a risk that [U.S. Department of Justice (“DOJ”)] will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages.” The Company also revealed it had received an initial civil investigative demand from the DOJ in July 2017 regarding Semler’s claims for reimbursement related to its peripheral artery disease QuantaFlo device. The Company further stated that it had participated in settlement discussions with the DOJ in February 2025, which were unsuccessful. Following this news, Semler’s stock price dropped.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Semler securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]